Basic Compazine Information

• INN (International Nonproprietary Name): Prochlorperazine
• Brand Names Available In Australia: not specified
• ATC Code: N05AB04
• Forms & Dosages: Tablets 5 mg, 10 mg; suppositories 25 mg; injectable ampoules/vials 5 mg/mL and 12.5 mg/mL; oral solution 5 mg/5 mL
• Manufacturers In Australia: not specified
• Registration Status In Australia: not specified
• OTC / Rx Classification: Prescription Only (Rx)

Latest Research Highlights (Australian + Global, 2022–2025)

Are clinicians still using compazine for sudden severe nausea and migraine vomiting?

Recent observational studies and pharmacovigilance summaries from 2022–2025 emphasise that prochlorperazine retains clinical value for acute severe nausea and migraine-associated vomiting, especially in community settings where quick oral or IM treatment is needed.

TGA adverse-event summaries (2022–2024) and international registries have flagged extrapyramidal symptoms and sedation in older adults as safety concerns, with acute dystonia and hypotension commonly reported among serious events that required emergency care.

Randomised controlled trials remain limited in number, and comparative meta-analyses continue to show ondansetron as superior for chemotherapy‑induced nausea, while phenothiazines such as prochlorperazine maintain a practical role in non‑chemotherapy acute emesis.

The International Nonproprietary Name is Prochlorperazine and its ATC code is N05AB04, confirming its classification among phenothiazine antipsychotics with antiemetic activity.

Emerging evidence supports short-course use (generally under seven days) for nausea, with specialist review recommended for psychotropic indications or longer therapy.

Data signals are higher in elderly and dementia cohorts, prompting regulators and clinicians to increase vigilance for EPS and sedation in older patients.

Local research in Australia remains limited in randomised designs, creating a need for TGA‑funded post‑marketing studies to better quantify comparative effectiveness and safety in Australian practice.

Clinical Effectiveness In Australia (PBS & TGA Insight)

How does Australian regulation and PBS affect compazine use?

TGA regulation and PBS access shape how prochlorperazine is used in Australian practice, with prescription‑only status guiding supply and monitoring.

Prochlorperazine (as proprietary brands or generics) is commonly used for acute severe nausea, migraine‑associated vomiting and, when antipsychotic effects are required, for psychiatric indications under specialist oversight.

Common international formulations include tablets (5 mg, 10 mg), suppositories and injectables, matching the ATC classification N05AB04 and prescription‑only scheduling.

PBS listings vary by indication, and where an item is subsidised adherence tends to improve for price‑sensitive patients, especially in regional and rural communities.

TGA adverse‑event reporting highlights extrapyramidal symptoms, sedation and hypotension as signals to monitor, and PBS dispensing data can show seasonal or regional spikes—for example during gastroenteritis seasons.

In clinical practice the bottom line is that prochlorperazine is effective for short courses to control acute emesis, and psychiatric uses should be specialist‑led with appropriate monitoring.

Indications & Expanded Uses (TGA-Approved And Common Off‑Label)

When might a pharmacist expect compazine to be recommended?

TGA‑approved uses broadly reflect antiemetic indications and treatment of psychotic disorders where antipsychotic action is indicated.

In Australian clinics prochlorperazine is commonly used for acute severe nausea and vomiting, migraine‑associated vomiting, and short‑term control of severe anxiety or agitation in selected cases.

Common off‑label uses include refractory vertigo, severe motion sickness and adjunctive antiemetic use in palliative care when other agents are unsuitable.

Typical dosing for severe nausea and vomiting is 5–10 mg orally three to four times a day, or 5–10 mg IM/IV once or twice daily for more severe or parenteral situations.

For psychosis initial adult dosing is often 5–10 mg three to four times daily with specialist titration, while short‑term anxiety dosing may be 5 mg three to four times daily (maximum commonly reported as 20 mg/day for short courses).

Off‑label prescribing should be documented, consented and guided by specialist advice where appropriate, and PBS restrictions may apply depending on indication.

Composition & Brand Landscape (Active Ingredient, Brands, Packaging)

Which brands or formulations should a buyer expect to see?

The active ingredient is prochlorperazine, often supplied as prochlorperazine maleate in many formulations.

Known brand names worldwide include Compazine, Compro and Stemetil, but many markets rely predominantly on generics in tablet, injectable and suppository forms.

Typical packaging and strengths found internationally are tablets 5 mg and 10 mg, suppositories 25 mg, injectable ampoules 5 mg/mL and 12.5 mg/mL and oral solution 5 mg/5 mL.

Manufacturers that supply prochlorperazine globally include Heritage Pharmaceuticals, Teva, Sandoz, Fresenius Kabi and Medochemie among many generic producers; local Australian manufacturers are not specified in public listings.

Brand discontinuations in some countries (for example Compazine in some markets) have increased reliance on generics and multiple suppliers.

Contraindications & Special Precautions (High‑Risk Australian Groups)

Who should avoid compazine or be closely monitored?

Absolute contraindications include known hypersensitivity to prochlorperazine or other phenothiazines, comatose patients or severe CNS depression, children under two years or under 10 kg for oral use, and patients with bone marrow depression.

Relative cautions include elderly patients (especially dementia‑related psychosis, where mortality risk is increased), Parkinson’s disease (can worsen parkinsonian symptoms), epilepsy (lowers seizure threshold), severe liver or kidney disease, significant cardiovascular disease, and prior neuroleptic malignant syndrome.

Pregnancy and breastfeeding require specialist risk–benefit discussions; indigenous and remote communities often have higher prevalence of comorbidities such as chronic kidney disease that mandate dose adjustment and closer monitoring.

Daily‑life restrictions include avoidance of driving or heavy machinery if sedated and strict avoidance of alcohol because it increases CNS depression.

Use a simple screening checklist in pharmacy practice: check allergies, current CNS depressant use, history of movement disorders, seizure history, and pregnancy/breastfeeding status before supply or counselling.

Dosage Guidelines (Standard Regimens & Adjustments)

What dosing should clinicians and patients expect?

Standard adult dosing for acute nausea is 5–10 mg orally three to four times daily, or 5–10 mg IM/IV once or twice daily for severe parenteral needs.

Pediatric dosing commonly cited is about 0.13 mg/kg orally every six to eight hours, but precise dosing varies by age and specialist guidance should be sought; avoid use under two years unless specifically advised.

For psychosis typical starting doses are 5–10 mg three to four times daily with specialist titration; older literature lists higher maximums but current practice emphasises minimal effective dosing and specialist oversight.

Adjust the dose down for elderly patients and those with hepatic or renal impairment, and monitor for extrapyramidal symptoms and hypotension.

Treatment durations are usually short for nausea (less than seven days), while psychotropic use requires review at two to four weeks and long‑term therapy only under specialist monitoring.

Interactions Overview (Drugs, Food, Monitoring)

Which medicines and substances increase risk when taken with compazine?

Prochlorperazine has clinically important interactions with other CNS depressants such as opioids, benzodiazepines, alcohol and sedating antihistamines, producing additive sedation.

Combining with other antimuscarinic agents increases anticholinergic effects, and co‑administration with QT‑prolonging drugs (some antipsychotics, macrolides, antifungals) raises cardiac risk, so caution and ECG monitoring may be required for high‑risk patients.

Concomitant use with certain antidepressants or bupropion can further lower the seizure threshold.

Pharmacists should review elderly patients for polypharmacy interactions and consider medication review for rural and Indigenous clients who may be on complex regimens.

Monitoring points include sedation level checks, routine EPS observation and ECG if multiple QT‑risk drugs are present.

Cultural Perceptions & Patient Habits (Australian Context)

What do Australian patients usually ask about compazine?

Patients commonly ask whether it will make them sleepy and whether it is available cheaply from big chains such as Chemist Warehouse, Priceline or TerryWhite Chemmart.

Trust in pharmacists for antiemetic advice is high, and online pharmacies plus telehealth e‑prescriptions have increased access in urban centres while rural and remote areas rely on local clinics and RFDS logistics for supply.

Patient forums and GP feedback report that prochlorperazine is viewed as effective for sudden severe nausea but there are ongoing concerns about sedation and long‑term movement disorder risk.

When counselling Indigenous clients, use culturally safe language, screen for comorbidities and ensure transport and follow‑up arrangements are clear.

Cost and PBS subsidy questions commonly influence adherence; many consumers ask which brand is strongest or whether it will make them sleepy, so clear, concise counselling is essential.

Availability & Pricing Patterns (Chains, Online, PBS Vs Private)

Where can Australians buy compazine and how much might it cost?

Generics are widely available through major Australian community pharmacies and accredited online pharmacies that accept e‑prescriptions.

PBS subsidy (where applicable) reduces out‑of‑pocket cost for concession card holders and PBS‑eligible patients, while private prescriptions vary by pharmacy and brand with chain discounts common in price‑sensitive markets.

Rural and remote supply can be affected by logistics, and injectable presentations may be limited in very remote clinics due to cold‑chain and staffing constraints.

In our online pharmacy, compazine is available without a prescription, with discreet delivery to Australia in 5–14 days.

Where PBS listing applies, dispensing volumes and TGA adverse‑event counts can be tracked to identify regional spikes or seasonal trends.

Comparable Medicines And Preferences (Alternatives In Australia)

Which antiemetics might be chosen instead of compazine?

Ondansetron is often preferred for chemotherapy‑ or postoperative‑induced nausea due to better tolerability, while metoclopramide is useful for gastroparesis with its own EPS risk profile.

Promethazine remains an option for motion sickness but is more sedating, and haloperidol is used in palliative or emergency settings as a potent antiemetic with antipsychotic effects.

Choice in Australian primary care balances PBS subsidy, side‑effect profile, comorbidities and patient preference, with prochlorperazine retained as a practical option for community acute emesis when ondansetron is not indicated or available.

FAQ

Will Compazine Make Me Sleepy?

Yes, drowsiness is a common side effect; avoid driving or operating machinery until you know how it affects you.

Can I Take Compazine With Alcohol?

No, alcohol increases central nervous system depression and will worsen sedation and dizziness.

Is Compazine On The PBS?

Some indications or formulations may be PBS‑listed; PBS item numbers vary by indication, so check with your GP or pharmacist for specific subsidy details.

What If I Get Muscle Stiffness Or Restlessness?

Those symptoms suggest extrapyramidal reactions; stop the medicine and seek urgent medical review—anticholinergic treatment may be required in acute cases.

Guidelines For Proper Use (Pharmacist Counselling & Patient Advice)

What should pharmacists tell a customer collecting compazine?

Confirm the indication, check allergies and current medicines to identify interactions and QT risk, and advise dosing using the lowest effective dose for the shortest practical duration for nausea.

Warn about sedation, advise strict avoidance of alcohol and explain driving and machinery restrictions if sedated.

Storage instructions are to keep at room temperature (15–30°C) and protect from moisture and light; injectable forms require specific handling instructions.

Missed‑dose advice is to take as soon as remembered unless it is nearly time for the next dose; do not double up doses.

Overdose presents with CNS and respiratory depression, hypotension and EPS; management is supportive, including activated charcoal if early and ICU care as required—there is no specific antidote.

For long‑term psychotropic use ensure routine monitoring including weight, metabolic profile and EPS scales, and plan deprescribing with a specialist where appropriate.

For telehealth prescriptions ensure e‑prescriptions are sent to a local pharmacy the patient can access, particularly important for rural Australia.

Delivery Across Australia

Quick Reference Tables

Typical Regimens By Indication

High‑Risk Drug Pairs And Actions

Further Advice And When To Seek Help

If a patient develops severe muscle stiffness, slow or irregular heartbeat, fainting, severe drowsiness, difficulty breathing or high fever, advise immediate presentation to emergency departments as these signs may indicate serious adverse reactions such as acute dystonia, hypotension or neuroleptic malignant syndrome.

For less severe side effects such as mild drowsiness, dry mouth or mild dizziness, recommend taking the lowest effective dose and arranging review with the prescriber or local pharmacist.

Pharmacies can assist with PBS queries, generic brand choices and practical counselling on storage and missed doses.

References And Notes

Information in this article is drawn from product and regulatory data for prochlorperazine, including standard dosing, formulation lists and safety warnings found in published product information.

Compazine, Stemetil and generic prochlorperazine formulations remain used internationally, with generics ensuring broad access.